SEARCH

SEARCH BY CITATION

References

  • Agathanggelou, A., Honorio, S., Macartney, D.P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J.A., Hosoe, S., Lerman, M.I., Minna, J.D., Maher, E.R. & Latif, F. (2001) Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20, 15091518.
  • Avet-Loiseau, H., Andree-Ashley, L.E., Moore, D., Mellerin, M.P., Feusner, J., Bataille, R. & Pallavicini, M.G. (1997) Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes, Chromosomes and Cancer, 19, 124133.
  • Bezieau, S., Devilder, M.C., Avet-Loiseau, H., Mellerin, M.P., Puthier, D., Pennarun, E., Rapp, M.J., Harousseau, J.L., Moisan, J.P. & Bataille, R. (2001) High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Human Mutations, 18, 212224.
  • Billadeau, D., Jelinek, D.F., Shah, N., LeBien, T.W. & Van Ness, B. (1995) Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Research, 55, 36403646.
  • Burbee, D.G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., Sekido, Y., Latif, F., Milchgrub, S., Toyooka, S., Gazdar, A.F., Lerman, M.I., Zabarovsky, E., White, M. & Minna, J.D. (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. Journal of National Cancer Institute, 93, 691699.
  • Chatterjee, M., Honemann, D., Lentzsch, S., Bommert, K., Sers, C., Herrmann, P., Mathas, S., Dorken, B. & Bargou, R.C. (2002) In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood, 100, 33113318.
  • Cheng, S.H., Chan, J.C., Liu, H.S., Chu, R.W., Chan, N.P., Lo, K.W., Tsang, K.S., Leung, Y. & Ng, M.H. (2002) Non-random chromosomal gains and losses in clonal plasma cells from Chinese multiple myeloma and monoclonal gammopathy of undetermined significance by comparative genomic hybridization. The Haematology Journal, 3 (Suppl. 1), 1092.
  • Cigudosa, J.C., Rao, P.H., Calasanz, M.J., Odero, M.D., Michaeli, J., Jhanwar, S.C. & Chaganti, R.S. (1998) Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood, 91, 30073010.
  • Corradini, P., Ladetto, M., Voena, C., Palumbo, A., Inghirami, G., Knowles, D.M., Boccadoro, M. & Pileri, A. (1993) Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 81, 27082713.
  • Dammann, R., Li, C., Yoon, J.H., Chin, P.L., Bates, S. & Pfeifer, G.P. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nature Genetics, 25, 315319.
  • Dammann, R., Takahashi, T. & Pfeifer, G.P. (2001) The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene, 20, 35633567.
  • Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R. & Futreal, P.A. (2002) Mutations of the BRAF gene in human cancer. Nature, 417, 949954.
  • Durie, B.G. (1998) Plasma cell disorders: recent advances in the biology and treatment. In: Recent Advances in Haematology (ed. by A.V.Hoffbrand), pp. 305327. Churchill Livingstone, New York.
  • Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842854.
  • Feinman, R., Sawyer, J., Hardin, J. & Tricot, G. (1997) Cytogenetics and molecular genetics in multiple myeloma. Hematology/Oncology Clinics of North America, 11, 125.
  • Ferlay, J., Bray, F., Pisani, P. & Parkin, D.M. (2001) GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide [Version 1.0]. WWW document. Available at: http://www-dep.iarc.fr/globocan/globocan.html.
  • Fong, L.Y., Lau, K.M., Huebner, K. & Magee, P.N. (1997) Induction of esophageal tumors in zinc-deficient rats by single low doses of N-nitrosomethylbenzylamine (NMBA): analysis of cell proliferation, and mutations in H-ras and p53 genes. Carcinogenesis, 18, 14771484.
  • Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D. & Baylin, S.B. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America, 93, 98219826.
  • Hiyama, T., Haruma, K., Kitadai, Y., Masuda, H., Miyamoto, M., Tanaka, S., Yoshihara, M., Shimamoto, F. & Chayama, K. (2002) K-ras mutation in helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. International Journal of Cancer, 97, 562566.
  • Lam, C.W., Poon, P.M., Tong, S.F. & Ko, C.H. (2001) Two novel CLN2 gene mutations in a Chinese patient with classical late-infantile neuronal ceroid lipofuscinosis. American Journal of Medical Genetics, 99, 161163.
  • Leung, S.C., Ng, M.H., Lau, K.M., Wong, W.S., Cheng, S.H., Chan, S., To, K.W. & Tsang, K.S. (2003) Hypermethylation profiling of p16, p15, Death-associated protein (DAP)-kinase, PTEN, RAR_2, RASSF1A in multiple myeloma. Proceedings of the American Association for Cancer Research, 44, 1137.
  • Liu, P., Leong, T., Quam, L., Billadeau, D., Kay, N.E., Greipp, P., Kyle, R.A., Oken, M.M. & Van Ness, B. (1996) Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood, 88, 26992706.
  • Lo, K.W., Kwong, J., Hui, A.B., Chan, S.Y., To, K.F., Chan, A.S., Chow, L.S., Teo, P.M., Johnson, P.J. & Huang, D.P. (2001) High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Research, 61, 38773881.
  • Neri, A., Murphy, J.P., Cro, L., Ferrero, D., Tarella, C., Baldini, L. & Dalla-Favera, R. (1989) Ras oncogene mutation in multiple myeloma. The Journal of Experimental Medicine, 170, 17151725.
  • Ng, M.H., Chung, Y.F., Lo, K.W., Wickham, N.W., Lee, J.C. & Huang, D.P. (1997) Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood, 89, 25002506.
  • Ng, M.H., Kan, A., Chung, Y.F., Wong, I.H., Lo, K.W., Wickham, N.W., Lei, K.I. & Lee, J.C. (1999a) Combined morphological and interphase fluorescence in situ hybridization study in multiple myeloma of Chinese patients. American Journal of Pathology, 154, 1522.
  • Ng, M.H., Wong, I.H. & Lo, K.W. (1999b) DNA methylation changes and multiple myeloma. Leukemia and Lymphoma, 34, 463472.
  • Ng, M.H., To, K.W., Lo, K.W., Chan, S., Tsang, K.S., Cheng, S.H. & Ng, H.K. (2001a) Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clinical Cancer Research, 7, 17241729.
  • Ng, M.H., Wong, N., Tsang, K.S., Cheng, S.H., Chung, Y.F. & Lo, K.W. (2001b) Recurrent chromosomal rearrangements involving breakpoints 3p21 and 19q13 in Chinese IgD multiple myeloma detected by G-banding and multicolor spectral karyotyping: a review of IgD karyotype literature. Human Pathology, 32, 10161020.
  • Ng, M.H., Wong, N., Lau, T.T., Tsang, K.S., Cheng, S.H., Chan, N.P., Tang, S.H., Lei, K.I. & Leung, Y. (2003) Chromosomal aberrations of multiple myeloma in Chinese patients at diagnosis: a study by combined G-banding and multicolor spectral karyotyping. Oncology Reports, 10, 587591.
  • Portier, M., Moles, J.P., Mazars, G.R., Jeanteur, P., Bataille, R., Klein, B. & Theillet, C. (1992) p53 and RAS gene mutations in multiple myeloma. Oncogene, 7, 25392543.
  • Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K.W., Vogelstein, B. & Velculescu, V.E. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature, 418, 934.
  • Sakamoto, A., Oda, Y., Itakura, E., Oshiro, Y., Tamiya, S., Honda, Y., Ishihara, A., Iwamoto, Y. & Tsuneyoshi, M. (2001) H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma. Human Pathology, 32, 12251231.
  • Semczuk, A., Schneider-Stock, R., Berbec, H., Marzec, B., Jakowicki, J.A. & Roessner, A. (2001) K-ras exon 2 point mutations in human endometrial cancer. Cancer Letter, 164, 207212.
  • Seremetis, S., Inghirami, G., Ferrero, D., Newcomb, E.W., Knowles, D.M., Dotto, G.P. & Dalla-Favera, R. (1989) Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes. Science, 243, 660663.
  • Vos, M.D., Ellis, C.A., Bell, A., Birrer, M.J. & Clark, G.J. (2000) Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. Journal of Biological Chemistry, 275, 3566935672.
  • Wijdenes, J., Vooijs, W.C., Clement, C., Post, J., Morard, F., Vita, N., Laurent, P., Sun, R.X., Klein, B. & Dore, J.M. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. British Journal of Haematology, 94, 318323.
  • Wong, I.H., Ng, M.H., Lee, J.C., Lo, K.W., Chung, Y.F. & Huang, D.P. (1998) Transcriptional silencing of the p16 gene in human myeloma-derived cell lines by hypermethylation. British Journal of Haematology, 103, 168175.